Recent Finacing
Recent Raise
SEngine Precision Medicine operates PARIS®, a CLIA-certified high-throughput platform that cultures patient-derived 3D tumor organoids to test targeted anticancer agents and combinations within weeks and advance drug candidate discovery.
